Thiazolidinedione drugs (TZDs) such as pioglitazone are approved by the US Food and
Drug Administration for the treatment of insulin resistance in type 2 diabetes. However …

Pioglitazone, an agonist at peroxisome proliferator-activated receptor gamma, is FDA-
approved for the treatment of insulin resistance in type 2 diabetes. Numerous studies in …

Abnormal sensations and pain are features of approximately 10% of all cases of diabetic
neuropathy and can cause marked diminution in the quality of life for these patients. The …

Chronic hyperglycemia in diabetes induces abnormal nerve pathologies, resulting in
diabetic neuropathy (DN). Sensory symptoms of DN can manifest as positive (painful) …

Diabetic neuropathic pain (DNP) plays a major role in decreased life quality of type 2
diabetes patients, however, the molecular mechanisms underlying DNP remain unclear …

Pain-sensing sensory neurons (nociceptors) of the dorsal root ganglia (DRG) and dorsal
horn (DH) can become sensitized (hyperexcitable) in response to pathological conditions …

Painful diabetic neuropathy (PDN) induces neuronal hyperactivity at the spinal cord and
periaqueductal gray (PAG), a key area in descending nociceptive modulation. Since the …

Chronic pain is a common complication of diabetes. The aim of the present study was to
characterise pain behaviour in a high fat diet/streptozotocin (HFD/STZ) model of diabetes in …

Neuropathic pain is the most common chronic complication of diabetes mellitus. The
mechanisms involved in the development of diabetic neuropathy include changes in the …

Diabetes mellitus is an increasingly common chronic medical condition. Approximately 30%
of diabetic patients develop neuropathic pain, manifested as spontaneous pain …